Novocure price target lowered to $42 from $49 at Wells Fargo

Wells Fargo lowered the firm’s price target on Novocure to $42 from $49 and keeps an Overweight rating on the shares. The firm says physician feedback points to METIS offering a clinical benefit to brain METS patients, although penetration will likely be lower than GBM. Next key milestones include LUNAR approval and PANOVA-3 top-line data, Wells adds.